| Title |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, November 2012
|
| DOI | 10.1158/1535-7163.mct-12-0358 |
| Pubmed ID | |
| Authors |
Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 62% |
| India | 1 | 8% |
| France | 1 | 8% |
| Unknown | 3 | 23% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 46% |
| Scientists | 4 | 31% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 22% |
| Student > Bachelor | 9 | 22% |
| Other | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Student > Master | 4 | 10% |
| Other | 5 | 12% |
| Unknown | 6 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 27% |
| Agricultural and Biological Sciences | 9 | 22% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 7 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2023.
All research outputs
#4,006,579
of 24,969,131 outputs
Outputs from Molecular Cancer Therapeutics
#770
of 4,036 outputs
Outputs of similar age
#28,069
of 188,587 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#12
of 45 outputs
Altmetric has tracked 24,969,131 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,036 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.